https://www.selleckchem.com/products/arn-509.html The current outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, has posed significant threats to international health. By Feb. 20, 2020, 74 576 cases have been confirmed and over 2 118 deaths have reported in the Chinese mainland. Chinese administrations have carried out immediate and prompt measures to stop the spread of the virus. Wuhan city has been shut down since Jan. 23, and more than 30 thousand medical workers have been recruited to Hubei province. Two temporary hospitals were constructed to treat severe pneumonia patients, and 15 mobile cabin hospitals were built to treat mild pneumonia cases. Significant improvement regarding the pathogenesis, epidemiology, and diagnosis and therapy for the COVID-19 has been achieved to stop the spread of the epidemics.The coronavirus disease 2019 (COVID-19) Global Rheumatology Alliance (C19-GRA) was formed in March 2020 as a grassroots organization to coordinate the response of the international rheumatology community to the pandemic [1]. The C19-GRA launched an international, secure, de-identified physician registry of patients with rheumatic diseases infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to provide insights into the management and treatment of COVID-19 in this population.Over 3 million paediatric patients globally and ~50 000 in the United States are estimated to be infected with HCV. Eradicating HCV in children helps prevent liver fibrosis, cirrhosis and hepatocellular carcinoma; reduces extra-hepatic manifestations of HCV; improves quality of life; and increases survival. The 2019 American Association for the Study of Liver Diseases-Infectious Diseases Society of America (AASLD-IDSA) guidelines now recommend direct-acting antiviral (DAA) treatment with an approved regimen for all children and adolescents with HCV infection aged ≥3 years. We conducted a descriptive review of the new DAA treatments for HCV infection i